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Abstract
Germline activating mutations of the protein tyrosine phosphatase SHP2 (encoded by PTPN11), a 
positive regulator of the RAS signalling pathway1, are found in 50% of patients with Noonan 
syndrome2. These patients have an increased risk of developing leukaemia3, especially juvenile 
myelomonocytic leukaemia (JMML), a childhood myeloproliferative neoplasm (MPN). Previous 
studies have demonstrated that mutations in Ptpn11 induce a JMML-like MPN through cell-
autonomous mechanisms that are dependent on Shp2 catalytic activity4–7. However, the effect of 
these mutations in the bone marrow microenvironment remains unclear. Here we report that 
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Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the 
development and progression of MPN through profound detrimental effects on haematopoietic 
stem cells (HSCs). Ptpn11 mutations in mesenchymal stem/progenitor cells and osteoprogenitors, 
but not in differentiated osteoblasts or endothelial cells, cause excessive production of the CC 
chemokine CCL3 (also known as MIP-1α), which recruits monocytes to the area in which HSCs 
also reside. Consequently, HSCs are hyperactivated by interleukin-1β and possibly other 
proinflammatory cytokines produced by monocytes, leading to exacerbated MPN and to donor-
cell-derived MPN following stem cell transplantation. Remarkably, administration of CCL3 
receptor antagonists effectively reverses MPN development induced by the Ptpn11-mutated bone 
marrow microenvironment. This study reveals the critical contribution of Ptpn11 mutations in the 
bone marrow microenvironment to leukaemogenesis and identifies CCL3 as a potential therapeutic 
target for controlling leukaemic progression in Noonan syndrome and for improving stem cell 
transplantation therapy in Noonan-syndrome-associated leukaemias.
In our recent study investigating the potential effects of Ptpn11 activating mutations in 
neural cells, we used the Ptpn11E76K mutation as a model and generated 
Ptpn11E76K/+Nestin-Cre+ mice with Ptpn11E76K mutation conditional knock-in mice 
(Ptpn11E76K-neo/+)5 and Nestin-Cre+ mice. We inadvertently found that Ptpn11E76K/+Nestin-
Cre+ mice developed a myeloid malignancy resembling MPN at the age of 7 months or older 
as evidenced by splenomegaly, and significantly increased numbers of myeloid cells in the 
peripheral blood and myeloid progenitors in the bone marrow (BM) (Fig. 1a, Extended Data 
Fig. 1a, b). Histopathological examination revealed hyperproliferation of myeloid cells in 
the BM and spleen (Extended Data Fig. 1c). Myeloid cells (Mac-1+Gr-1+) (Fig. 1b) and 
inflammatory monocytes (CD115+Gr-1+) (Extended Data Fig. 1d) were significantly 
increased in these tissues. Moreover, extensive myeloid cell infiltration in the liver and lung 
was detected (Fig. 1b, Extended Data Fig. 1c). The loxP-flanked neo cassette with a stop 
codon, which inactivated the targeted Ptpn11E76K-neo allele5, was intact in the MPN cells of 
these mice (Fig. 1c), indicating that the myeloid malignancy was not caused by the Ptpn11 
mutation in haematopoietic cells. Previous studies have shown that Nestin is also expressed 
in BM mesenchymal stem/progenitor cells (MSPCs) in addition to neural cells, and that 
perivascular Nestin+ MSPCs constitute unique sinusoidal vascular and arteriolar HSC 
niches8,9. We therefore examined targeted Ptpn11 alleles in BM-derived MSPCs and found 
that the inhibitory neo cassette was deleted in approximately 95% of these cells (Fig. 1c). 
Interestingly, the frequency and absolute numbers of primitive haematopoietic progenitors 
and stem cells in the BM were markedly decreased in Ptpn11E76K/+Nestin-Cre+ mice, 
whereas these cells in the spleen were increased (Fig. 1d, Extended Data Fig. 1e–g). The fact 
that the numbers of mature myeloid cells and myeloid progenitors increased whereas stem 
cells decreased implied aberrant activation and accelerated differentiation of HSCs in the 
BM. Indeed, the number of quiescent HSCs in the G0 phase in Ptpn11E76K/+Nestin-Cre+ 
mice decreased by twofold, whereas that of HSCs in the G1 or S/G2/M phases doubled (Fig. 
1e). HSCs in these mice had reduced apoptosis (Extended Data Fig. 1h). Assessment of 
intracellular signalling activities demonstrated that Erk, Akt and NF-κB pathways were 
highly activated in the HSCs of Ptpn11E76K/+Nestin-Cre+ mice (Fig. 1f). The MPN 
developed in chronic-phase Ptpn11E76K/+Nestin-Cre+ mice was not transferable to wild-type 
transplants, but MPN cells from terminally ill mice reproduced the same disease in 50% of 
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the recipients (Fig. 1g), possibly owing to the acquisition of unknown genetic mutations that 
conferred self-renewal capability to MPN cells. At a 6–8-month follow up, 8 of 12 lethally 
irradiated Ptpn11E76K/+Nestin-Cre+ mice that were transplanted with wild-type BM cells 
developed donor-cell-derived MPN (Fig. 1g, Extended Data Fig. 1i), verifying the robust 
pathogenic effects of the Ptpn11E76K/+ mutation in Nestin+ BM stromal cells. These results 
suggested that the Ptpn11-mutated BM microenvironment drove MPN development by 
hyperactivation of resident wild-type HSCs. This notion was further supported by the 
observation that aberrant HSC activation occurred before full development of MPN in 
Ptpn11E76K/+Nestin-Cre+ mice (Extended Data Fig. 1j).
As PTPN11 mutations in Noonan syndrome are present ubiquitously, we next determined 
the effect of the Ptpn11-mutated microenvironment on HSCs that also carried Ptpn11 
mutations. We compared Ptpn11E76K/+Mx1-Cre+ mice, in which Cre was expressed in 
haematopoietic cells as well as BM stromal cells10,11 following administration of 
polyinosinic–polycytidylic acid (pI–pC), with Ptpn11E76K/+Vav1-Cre+ mice, in which 
constitutive Cre expression was restricted to haematopoietic cells and part of endothelial 
cells (see below). The disease phenotypes of Ptpn11E76K/+Vav1-Cre+ mice were much less 
severe (Fig. 2a, b, Extended Data Fig. 2a). Furthermore, at a 12-month follow-up check, 
MPN in 19% of Ptpn11E76K/+Vav1-Cre+ mice developed into acute leukaemia, as opposed 
to 63% of Ptpn11E76K/+Mx1-Cre+ mice (Fig. 2c). The inhibitory neo cassette in the mutated 
Ptpn11 allele was deleted from haematopoietic cells to the same extent in both lines of mice. 
However, neo deletion from MSPCs, osteoblasts and endothelial cells was detected in 
Ptpn11E76K/+Mx1-Cre+ but not Ptpn11E76K/+Vav1-Cre+ mice (except for partial deletion 
from endothelial cells) (Fig. 2d). The differences in the severity and prognosis of MPN 
between these two lines of mice do not appear to be associated with pI–pC administration or 
the times/stages when the disease mutations were induced (Extended Data Fig. 2b–e). 
Furthermore, no donor-cell-derived MPN developed in Ptpn11E76K/+Vav1-Cre+ mice 
transplanted with wild-type BM cells, in contrast to the 75% incidence of donor-cell-derived 
MPN in Ptpn11E76K/+Mx1-Cre+ recipients (Fig. 2e, f, Extended Data Fig. 3a, b). Wild-type 
donor HSCs were also highly activated in Ptpn11E76K/+Mx1-Cre+, but not 
Ptpn11E76K/+Vav1-Cre+ recipients owing to aberrantly enhanced cell signalling activities 
(Fig. 2g, h). Similar results were obtained from the Noonan syndrome mutation Ptpn11D61G 
global knock-in mice, which were born with a developmental disorder resembling Noonan 
syndrome and developed JMML-like MPN4. Transplantation of wild-type BM cells into 
lethally-irradiated Ptpn11D61G/+ mice initially reversed MPN. The mice appeared to be 
cured during the first 3 months after transplantation, but 8 out of 14 then developed donor-
cell-derived MPN in the next 5 months (Extended Data Fig. 3c).
To further define the cell types in the Ptpn11-mutated BM microenvironment that have an 
important role in driving/enhancing MPN development, we generated cell-type-specific 
Ptpn11E76K/+ knock-in mice and monitored them for one and a half years. The Ptpn11E76K/+ 
mutation in Prx1-expressing broad mesenchymal cells, Lepr+ mesenchymal cells, Osterix 
(Osx1)-expressing osteoprogenitors (all of which contain/overlap with Nestin+ 
MSPCs12–15), but not Osteocalcin (Oc)-expressing differentiated osteoblasts or VE-
cadherin-expressing endothelial cells, induced MPN (Table 1, Extended Data Fig. 4a, b). 
The deletion efficiency of neo from mutated Ptpn11 alleles in MSPCs generally correlated 
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with the latency and severity of MPN that developed in these lines of cell-type-specific 
mutant mice (Extended Data Fig. 4c), suggesting that MSPCs and/or osteoprogenitors were 
responsible for the leukaemogenic effects of the Ptpn11-mutated BM microenvironment. 
HSCs were hyperactivated only in the lines of mice that developed MPN (Table 1), further 
underscoring the effect of HSC hyperactivation on the myeloid malignancy induced/
enhanced by the Ptpn11 mutation in MSPCs and osteoprogenitors.
We next sought to identify the mechanisms by which Ptpn11-mutated MSPCs and 
osteoprogenitors activate HSCs (wild type or mutant with the same Ptpn11 mutation). 
Compared to wild-type HSCs, Ptpn11E76K/+ mutant HSCs had accelerated myeloid 
differentiation owing to cell autonomous effects5, regardless of whether they were co-
cultured with wild-type or Ptpn11E76K/+ BM stromal cells or MSPCs (Extended Data Fig. 
5a). Unexpectedly, Ptpn11E76K/+ stromal cells and MSPCs had no significant activating 
effects on either Ptpn11E76K/+ or wild-type HSCs (Extended Data Fig. 5a). Similar results 
were obtained when HSCs and MSPCs were co-cultured in two separate chambers that still 
allowed growth factors/cytokines to freely cross (Extended Data Fig. 5b). Interestingly, 
cytokine–chemokine array analyses for the BM plasma revealed that proinflammatory 
cytokines IL-1β and TREM-1, but not IL-6 (refs 16, 17), G-CSF18,19, GM-CSF16, TNF-
α17,19,20, or IL-1α17 that are known to be involved in MPN, were substantially increased in 
Ptpn11E76K/+Mx1-Cre+ mice (Fig. 3a). In addition, the inflammatory CC chemokine CCL3 
and TIMP-1, an inhibitor of matrix metalloproteinases generated by monocytes21, were 
increased, whereas CXCL12 (SDF-1), a chemokine important for HSC retention in the 
niche22,23, was decreased (Fig. 3a). The spleen plasma from Ptpn11E76K/+Mx1-Cre+ mice 
also showed markedly increased levels of CCL3, CCL12 and CCL4 (Extended Data Fig. 6a).
To comprehensively identify the protein factors that were aberrantly produced by MSPCs 
with Ptpn11 mutations, we performed RNA-sequencing gene expression profiling analyses 
(GEO number GSE81311). mRNA levels of Ccl3, Ccl12, and Ccl4 were increased by 6.5-, 
3.7-, and 1.7-fold (log2 scale), respectively, whereas expression of Cxcl12 was decreased by 
1.8-fold in Ptpn11E76K/+ MSPCs (Extended Data Fig. 6b). In addition, the anti-inflammatory 
cytokine IL-1 receptor antagonist (Il1ra), was also increased by 4.6-fold. Cytokine–
chemokine array analyses with MSPC culture medium confirmed that the amount of CCL3, 
CCL12, and IL-1ra proteins secreted by Ptpn11E76K/+ MSPCs was indeed greatly increased 
(Fig. 3b). Levels of IL-1β and CCL3 in the BM plasma (Fig. 3c) and CCL3 in the culture 
medium of MSPCs (Fig. 3d) isolated from microenvironmental cell-type-specific 
Ptpn11E76K/+ mice correlated closely with the latency and incidence of MPN in these lines 
of mice. Remarkably, IL-1β production from PTPN11-mutated leukaemic cells from 
patients with JMML also increased by 7.9-fold to 65.7-fold over that of healthy donor cells 
(Fig. 3e). The amount of CCL3 produced by MSPCs derived from PTPN11-mutation-
positive Noonan syndrome patients with JMML complications increased by 3.3-fold to 43.0-
fold, whereas CXCL12 was decreased compared to those secreted by normal human MSPCs 
(Fig. 3f). The direct effects of these aberrantly produced cytokines/chemokines on HSCs 
were then determined. Interestingly, although IL-1β robustly activated HSCs to differentiate 
towards myeloid cells and monocytes, CCL3, CCL4, and CCL12—which were over-
produced by Ptpn11-mutated MSPCs—did not show any activating effects on HSCs 
(Extended Data Fig. 6c).
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We next investigated the in vivo consequences of the excessive CC chemokines produced by 
Ptpn11-mutated MSPCs. Nestin+ MSPCs and Osteopontin+ osteoblasts were increased in 
Ptpn11E76K/+Nestin-Cre+ mice (Extended Data Fig. 7a). Frequencies of colony-forming unit 
fibroblasts (CFU-F) in the BM, indicative of MSPCs, were increased to various extents 
(Extended Data Fig. 7b) that were commensurate with the induction efficiencies of the 
Ptpn11E76K/+ mutation in MSPCs in various lines of microenvironmental cell-type-specific 
knock-in mice (Extended Data Fig. 4c). Indeed, MSPCs isolated from Ptpn11E76K/+Nestin-
Cre+ mice grew much faster with significantly enhanced cycling due to elevated cell 
signalling activities caused by the activating mutation of Shp2 (Extended Data Fig. 7c–e). In 
addition, osteogenesis was enhanced in Ptpn11E76K/+Nestin-Cre+ mice as evidenced by 
markedly increased thickness of the calvarium (Fig. 4a). Most notably, Nestin+ MSPCs in 
Ptpn11E76K/+Nestin-Cre+ (Fig. 4b) and Ptpn11E76K/+Prx1-Cre+ mice (Extended Data Fig. 
8a) were frequently surrounded by CD115+Gr-1+ inflammatory monocytes, but not F4/80+ 
macrophages (Extended Data Fig. 8b). This was probably attributable to the excessive CCL3 
and possibly other CC chemokines secreted from Ptpn11E76K/+ MSPCs, because these 
chemokines strongly induce chemotaxis of monocytes24,25. Consequently, the percentage of 
HSCs surrounded by CD115+Gr-1+ monocytes greatly increased (Fig. 4c) and the 
percentage of HSCs close to Nestin+ MSPCs decreased (Fig. 4d). Furthermore, the distance 
of HSCs from CD31+CD144+ endothelial cells doubled (Extended Data Fig. 8c) and the 
percentage of HSCs residing in the megakaryocyte niches significantly decreased (Extended 
Data Fig. 8d) in Ptpn11E76K/+Nestin-Cre+ mice. Thus, it appears that persistent high levels 
of proinflammatory cytokines produced by the monocytes (with or without the Ptpn11 
mutation) recruited by Ptpn11-mutated MSPCs/osteoprogenitors hyperactivated 
neighbouring HSCs with the same mutation or wild-type donor HSCs and displaced them 
from MSPC, endothelial cell, and megakaryocyte niches that are essential for maintaining 
HSC dormancy8,9,26–29, resulting in exacerbated MPN or donor-cell-derived MPN.
To validate the role of excessive CCL3 in mediating the pathogenic effects of the Ptpn11-
mutated BM microenvironment, we treated Ptpn11E76K/+Osx1-Cre+ mice with the CCL3 
receptor (CCR1 and CCR5) antagonists. As shown in Figure 4e–g and Extended Data Figure 
9a, b, treatment with CCR1 and CCR5 antagonists for 3 weeks effectively reversed MPN 
phenotypes, as determined by spleen weights, total white blood cell counts in the peripheral 
blood, and myeloid cells in the BM, spleen, and peripheral blood. The therapeutic effects 
correlated with the restoration of the quiescence and the size of the HSC pool (Fig. 4h, 
Extended Data Fig. 9c). We also treated Ptpn11E76K/+Mx1-Cre+ mice with CCL3 receptor 
antagonists. Similar effects, but to a lesser extent, were observed (Extended Data Fig. 10a–
e).
In summary, our mouse genetics studies have demonstrated that Ptpn11 mutations in the BM 
microenvironment have pathogenic effects on resident HSCs, promoting/inducing 
leukaemogenesis. Nevertheless, as Noonan syndrome involves various mutations in PTPN11 
and other genes (such as RAS, CBL, B-RAF, SOS1, and SHOC2), it remains to be 
determined whether the leukaemogenic effects of microenvironmental PTPN11 mutations 
depend on the potencies of these mutations, and whether Noonan-syndrome-associated 
mutations in other genes in the BM microenvironment also have detrimental effects. Clinical 
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phenotype–genotype correlative studies in a large cohort of Noonan syndrome patients are 
required to address these questions.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to these 
sections appear only in the online paper.
Methods
Mice
Generation of Ptpn11E76K-neo/+mice have previously been reported5. A neo cassette with a 
stop codon flanked by loxP sites was inserted in the second intron of the Ptpn11 allele 
followed by the mutation GAA (E) to AAA (K) at the amino acid 76 encoding position in 
the third exon. The mice were backcrossed to C57BL/6 mice for more than 10 generations. 
Ptpn11D61G/+ mice4were originally imported from Beth Israel Deaconess Medical Center. 
Nestin-Cre+30, Mx1-Cre+31, Vav1-Cre+32, Prx1-Cre+33, Lepr-Cre+34, Osx1-Cre+35, Oc-
Cre+36, and VE-Cadherin-Cre+-ERT2 (ref. 37) transgenic mice used in this study were 
purchased from the Jackson Laboratory or obtained from the investigators who originally 
developed the mouse lines. Mice of the same age, sex, and genotype were mixed and then 
randomly grouped for subsequent analyses (investigators were not blinded during allocation, 
during experiments and outcome assessment). All mice were kept under specific-pathogen-
free conditions in the Animal Resources Center at Case Western Reserve University and 
subsequently Emory University Division of Animal Resources. All animal procedures 
complied with the NIH Guidelines for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee.
Ptpn11E76K/+Mx1-Cre+ mice and Ptpn11+/+Mx1-Cre+ littermates (8 weeks old) were 
administered with i.p. injection of 3 doses of pI–pC (1.0 µg per g body weight) every other 
day over 5 days. Ptpn11E76K/+VE-Cadherin-Cre+-ERT2 mice and Ptpn11+/+VE-Cadherin-
Cre+-ERT2 littermates (4–6 weeks old) were administered with i.p. injection of 3 doses of 
tamoxifen (9.0 mg per 40 g body weight) every other day over 5 days. Mice were analysed 
at the indicated time points after pI–pC or tamoxifen administration. Acute leukaemia 
progression in pI–pC administered Ptpn11E76K/+Mx1-Cre+ and Ptpn11E76K/+Vav1-Cre+ 
mice was determined as we previously described5. No statistical methods were used to 
predetermine sample size.
Patient specimens
De-identified BM biopsies from PTPN11-mutation-positive Noonan syndrome patients with 
JMML or non-syndromic PTPN11 mutation-positive patients with JMML were obtained 
from the University of California, San Francisco Tissue Cancer Cell Bank and Children’s 
Healthcare of Atlanta, Emory University. Informed consent was obtained from all subjects. 
The experiments involving human subjects were reviewed and approved (Exemption IV) by 
the Institutional Review Board of Emory University.
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BM cell transplantation
BM cells (2 × 106) collected from indicated donor mice were transplanted into lethally 
irradiated (1,100 cGy) recipient mice with the indicated genotypes through tail vein 
injection. Recipients were monitored for MPN development for 6–8 months.
Quantitative real-time PCR (qPCR)
To determine the abundance of the neo cassette in the targeted Ptpn11 allele, genomic DNA 
of haematopoietic cells, MSPCs, or other indicated cells was extracted with a ZR-Duet 
DNA/RNA MiniPrep extraction kit (Zymo Research). The abundance of the neo cassette 
was then quantified by qPCR using the Applied Biosystems 7500 Fast Real-Time PCR 
System. The PCR primers used were: 5′ -TGGGAAGACAATAGCAGGCA-3′ and 5′ -
CCCACTCA CCTTGTCATGTA-3′.
Fluorescence-activated cell sorting (FACS)
The pool size, cell cycle status, apoptosis, and cell signalling activities of HSCs were 
analysed by multiparameter FACS analyses, as previously described38. In brief, for the HSC-
pool-size analysis, fresh BM cells were stained with the following antibodies (eBiosciences, 
San Diego, unless otherwise noted): lineage antibodies (B220 (RA3-6B2), CD3 (145-2C11), 
Gr-1 (RB6-8C5), Mac-1 (M1/70), and Ter-119 (TER-119)), anti-Sca-1 (D7, BD 
Biosciences), anti-c-Kit (2B8), anti-CD150 (TC15-12F12.2, BD Biosciences), anti-CD48 
(HM48-1), and anti-Flk2 (A2F10.1). Lin−Sca-1+c-Kit+CD150+CD48−Flk2− cells were 
quantified as HSCs. For the cell cycle analysis, freshly collected BM cells were stained for 
HSCs as above. Cells were then fixed and permeabilized using a Cytofix/Cytoperm kit (BD 
Biosciences), stained with Ki-67 antibody, and further incubated with Hoechest 33342 (20 
µg ml−1). For the apoptosis analysis, BM cells were stained for HSCs, and then incubated 
with Annexin V and 7-amino-actinomycin D (BD Biosciences). For cell signalling analyses, 
BM cells were stained for HSCs, fixed and permeabilized using a Cytofix/Cytoperm kit, and 
then stained with anti-phospho-Erk (mouse IgG) (E-4, Santa Cruz Biotechnology), anti-
phospho-Akt (rabbit IgG) (C31E5E, Cell Signaling), or anti-phospho-NF-κB (rabbit IgG) 
(93H1, Cell Signaling) antibodies, washed and further incubated with AlexaFluor488-
conjugated secondary antibodies (goat anti-mouse IgG or goat anti-rabbit IgG) (Life 
technologies). Phosphorylation levels of these signalling proteins were determined by mean 
fluorescence intensities (MFI) of gated cells. Data were collected on BD LSR II Flow 
Cytometer (BD Biosciences) and analysed with FlowJo (Treestar).
In vitro HSC culture
HSCs (Lin−Sca-1+c-Kit+CD150+CD48−Flk2−) sorted from wild-type C57BL/6 mice were 
cultured in StemSpan medium supplemented with SCF (50 ng ml−1), Flt3 ligand (50 ng 
ml−1), TPO (50 ng ml−1), IL-3 (20 ng ml−1), and IL-6 (20 ng ml−1) in the presence of IL-1β 
(10 ng ml−1), CCL3 (20 ng ml−1), CCL4 (20 ng ml−1), or CCL12 (20 ng ml−1). Six days 
later, cells were collected and analysed for Mac-1+ myeloid cells, F4/80+ macrophages, and 
CD115+ monocytes.
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MSPC isolation and enrichment
Mouse MSPCs were enriched following a standard protocol39. In brief, BM was collected 
from long bones. The bones were then crushed and digested with collagenase type II (2.5 mg 
ml−1) (Worthington Biochemical Corporation). BM cells and digested bone fragments were 
combined and cultured in DMEM supplemented with 15% fetal bovine serum (FBS). For 
human MSPC derivation, only BM cells were used. Suspension haematopoietic cells were 
removed after 24 h. Medium was replenished every 72 h. Colonies of MSPCs appeared 6–8 
days after initial plating. To further purify MSPCs, cells were collected and stained with 
biotin-conjugated CD45 antibody and anti-biotin microbeads. CD45+ haematopoietic cells 
were depleted using MACS separation columns (Miltenyi Biotec Inc.). The purity of MSPCs 
(>95%) was further confirmed according to the (CD45−CD140α+Sca-1+) phenotypes39 by 
multiparameter FACS analyses.
Fibroblast colony-forming unit (CFU-F) and colony forming unit-granulocyte/macrophage 
(CFU-GM) assays
For the CFU-F assay, 2 × 106 unfractionated BM cells were plated and cultured for 10–14 
days as described above. Cells were stained with 0.5% crystal violet (Sigma-Aldrich) in 
10% methanol for 20 min. Colonies formed by more than 50 fibroblast-like cells were 
counted under a light microscope. For the CFU-GM assay, freshly collected BM cells (2 × 
104 cells ml−1) were seeded in 0.9% methylcellulose IMDM medium containing 30% FBS, 
glutamine (10−4 M), β-mercaptoethanol (3.3 × 10−5 M), and IL-3 (1 ng ml−1) or GM-CSF (1 
ng ml−1). After 7 days of culture at 37 °C in a humidified 5% CO2 incubator, colonies 
(primarily CFU-GM) formed by more than 50 haematopoietic cells were counted under an 
inverted microscope.
RNA-sequencing analysis
MSPCs (CD45−Ter-119−CD31−CD140α+Sca-1+)39 were freshly isolated from the BM of 
Ptpn11E76K/+Nestin-Cre+ and Ptpn11+/+Nestin-Cre+ mice. RNA was extracted using the 
RNeasy Midi kit (Qiagen). Total RNA samples were enriched for polyadenylated transcripts 
using the Oligotex mRNA Mini kit (Qiagen), and strand-specific RNA-seq libraries were 
generated using PrepX RNA library preparation kits (IntegenX), following the 
manufacturer’s protocol. After cleanup with AMPure XP beads (Beckman Coulter) and 
amplification with Phusion High-Fidelity polymerase (New England BioLabs), RNA 
libraries were sequenced on a HiSeq 4000 instrument to a depth of at least 20 million reads. 
The correlation coefficient between the two groups is 0.954, which verifies that the method 
is accurate (Extended Data Fig. 6b). Before differential gene expression analysis, for each 
sequenced library, the read counts were adjusted by edgeR program package through one 
scaling normalized factor. Differential expression analysis of two conditions was performed 
using the DEGSeq R package (1.12.0). The P values were adjusted using the Benjamini–
Hochberg method. Corrected P value of 0.005 and log2(fold change) of 1 were set as the 
threshold for significantly different expression.
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Chemokine–cytokine array analyses
Femurs were dissected from Ptpn11E76K/+Mx1-Cre+ mice and Ptpn11+/+Mx1-Cre+ 
littermates 12 weeks after pI–pC administration. BM plasma was collected by flushing one 
femur with 1.0 ml of phosphate buffered saline (PBS). MSPCs derived from pI–pC-
administered Ptpn11E76K/+Mx1-Cre+ and Ptpn11+/+Mx1-Cre+ mice were cultured (4 × 106 
cells in 2.0 ml medium) in serum-free DMEM for 48 h. The culture medium was then 
collected. BM plasma or MSPC culture medium were analysed with Mouse Cytokine 
Antibody Array blots (R&D Systems) following the instructions provided by the 
manufacturer.
ELISA and cytometric bead array assay
BM plasma collected from one femur and one tibia in 500 µl PBS. Culture medium was 
collected from mouse MSPCs (4 × 106 cells per 2.0 ml) at second or third passages cultured 
in serum-free DMEM for 48 h. These samples were assayed for levels of IL-1β and CCL3 
using enzyme-linked immunosorbent assay (ELISA) kits (IL-1β: eBioscience; CCL3: R&D 
Systems) following the instructions provided by the manufacturers. To determine multiple 
cytokines/chemokines produced by human MSPCs, MSPCs (2 × 104 cells ml−1) were 
cultured in serum-free StemSpan medium for 72–96 h. To determine multiple protein factors 
produced by cells from patients with JMML, JMML cells (2 × 105 cells ml−1) were cultured 
in StemSpan medium supplemented with human SCF (50 ng ml−1), human Flt3 ligand (50 
ng ml−1), and human TPO (50 ng ml−1) for 72 h. The culture medium was then collected 
and cytokine/chemokine levels were determined by the BD Cytometric Bead Array Flex 
Sets (BD Biosciences) following the manufacturer’s instructions. Human CXCL12 levels in 
MSPC culture medium were measured using a Human CXCL12/SDF-1 alpha Quantikine 
ELISA Kit (R&D systems).
Immunofluorescence staining
Frozen tissue sections prepared from 4% paraformaldehyde-fixed and decalcified bones 
were thawed at room temperature and then rehydrated with PBS. The slides were stained 
with the following antibodies (eBiosciences, San Diego, unless otherwise noted) following 
standard procedures: anti-Osteopontin (Abcam), anti-Nestin (MAB353, Millipore), anti-Gr-1 
(RB6-8C5), anti-Mac-1 (M1/70), anti-B220 (RA3-6B2), anti-Ter-119 (TER-119), anti-CD3 
(145-2C11, BD Biosciences), anti-CD115 (AFS98), anti-CD150 (TC15-12F12.2, BD 
Biosciences), anti-CD31 (MEC13.3, Biolegend), anti-CD48 (HM48-1), and anti-CD41 
(eBioMWReg30) antibodies. Images were acquired using Olympus Confocal Laser 
Scanning Biological Microscope FV1000 equipped with four lasers ranging from 405 to 635 
nm. Images were processed with ImageJ software.
Administration of CCR1 and CCR5 antagonists
Ptpn11E76K/+Osx1-Cre+ mice (6–7 month old) and Ptpn11E76K/+Mx1-Cre+ mice (4 weeks 
after pI–pC administration) were treated daily via subcutaneous injection with the CCR1 
antagonist BX471 ((2R)-1-((2-((aminocarbonyl)amino)-4-chlorophenoxy)acetyl)-4-((4-
fluorophenyl)methyl)-2-methylpiperazine) purchased from Tocris Bioscience (50 mg kg−1 of 
body weight). These animals also received the CCR5 antagonist Maraviroc (4,4-difluoro-N-
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((S)-3-(3-(3-isopropyl-5-methyl-4H-1,2, 4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl)-1-
phenylpropyl)cyclohexanecarbox-amide) obtained from Selleck Chemicals (0.3 mg ml−1 in 
the drinking water). Control Ptpn11E76K/+Osx1-Cre+ mice and Ptpn11E76K/+Mx1-Cre+ mice 
were given vehicle (70% ethanol and 0.5% DMSO for subcutaneous injections, and 1% 
DMSO in drinking water). Mice were treated for 23 days and then killed for subsequent 
analyses.
Statistics
Data are presented as mean ± s.d. of all mice analysed in multiple experiments (that is, 
biological replicates). Statistical significance was determined using unpaired two-tailed 
Student’s t test. For HSC imaging analyses, two-tier tests were used to first combine 
technical replicates and then evaluate biological replicates. To determine statistical 
significance in the incidences of MPN development and malignant progression, Fisher’s 
exact tests were performed. *P < 0.05; **P < 0.01; ***P < 0.001; N.S., not significant in 
Extended Data Figs 2, 5.
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Extended Data
Extended Data Figure 1. Ptpn11E76K/+ mutation in MSPCs induces MPN by aberrant activation 
of neighbouring wild-type HSCs in Ptpn11E76K/+Nestin-Cre+ mice
a, Peripheral blood collected from 7–12-month-old Ptpn11E76K/+Nestin-Cre+ mice with 
MPN and Ptpn11+/+Nestin-Cre+ littermates were analysed for percentages of neutrophils 
and lymphocytes (n = 15 mice per group). b, BM cells (2 × 104 cells) freshly collected from 
Ptpn11E76K/+Nestin-Cre+ mice with MPN and Ptpn11+/+Nestin-Cre+ littermates (n = 4 mice 
per group) were assayed for haematopoietic colony-forming units in 0.9% methylcellulose 
IMDM medium containing 30% FBS, glutamine (10−4 M), β-mercaptoethanol (3.3 × 10−5 
M), and IL-3 (1.0 ng ml−1) or GM-CSF (1.0 ng ml–1). After 7 days of culture at 37 °C in a 
humidified 5% CO2 incubator, haematopoietic cell colonies (primarily CFU-GM) derived 
from myeloid progenitors were counted under an inverted microscope. c, Femurs, spleens, 
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livers and lungs were processed for histopathological examination (haematoxylin and eosin 
staining) (n = 4 mice per group). Representative pictures are shown. d–h, BM cells and 
splenocytes were collected from Ptpn11E76K/+Nestin-Cre+ mice with MPN and 
Ptpn11+/+Nestin-Cre+ littermates. CD115+Gr-1+ monocytes in the BM (n = 4 mice per 
group) (d), frequencies of LSKs (Lin−Sca-1+c-Kit+) in the BM (n = 8 mice per group) (e), 
absolute number of HSCs in two femurs and two tibias (n = 10 mice per group) (f), 
frequencies of LSKs in the spleen (n = 8 mice per group) (g), and apoptotic cells in the HSC 
population in the BM (n = 6 mice per group) (h) were assayed by multiparameter FACS 
analyses. i, BM cells collected from wild-type BoyJ mice were transplanted into 6-month-
old Ptpn11E76K/+Nestin-Cre+ and Ptpn11+/+Nestin-Cre+ mice. Recipients were monitored 
for MPN development for 6–8 months. Percentages of donor cell (CD45.1+)-derived Mac-1+ 
myeloid cells in the peripheral blood (n = 5 mice per group) and BM (n = 8 mice per group) 
of recipients were determined. j, Frequencies of HSCs in the BM from Ptpn11E76K/+Nestin-
Cre+ mice that had not yet manifested MPN and Ptpn11+/+Nestin-Cre+ littermates (n = 4 
mice per group) were assayed as above. Data shown in a, b, d–j are mean ± s.d. of all mice 
examined; *P < 0.05; **P < 0.01; ***P < 0.001. Source Data for this figure are available 
online.
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Extended Data Figure 2. Ptpn11E76K/+ mutation in the BM stroma enhances MPN development 
from mutant HSCs with the same mutation in Ptpn11E76K/+Mx1-Cre+ mice
a, Tissues collected from Ptpn11+/+Mx1-Cre+, Ptpn11E76K/+Mx1-Cre+ (8 weeks after pI–pC 
administration), and Ptpn11E76K/+Vav1-Cre+ mice at 16-week old (n = 3 mice per group) 
were processed for histopathological examination (haematoxylin and eosin staining). 
Representative pictures are shown. b–d, Ptpn11E76K/+Vav1-Cre+ mice (4 weeks old) (n = 3 
mice per group) were administered pI–pC or PBS, as described in Methods. Spleen weights 
(b), Mac-1+Gr-1+ myeloid cells in the BM, spleen, and liver (c), the cycling status of HSCs 
(d) were analysed 16 weeks after pI–pC administration. e, Timed pregnant 
Ptpn11E76K/+Mx1-Cre− female mice (13.5 days post coitum) that were mated with 
Ptpn11+/+Mx1-Cre+ male mice were administered pI–pC as above. Ptpn11E76K/+Mx1-Cre+ 
pups delivered by these female mice were identified. The efficiencies of neo deletion from 
targeted Ptpn11 alleles in haematopoietic cells and MSPCs of these mice were 
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approximately 95%. Mac-1+Gr-1+ cells in the peripheral blood of Ptpn11+/+Mx1-Cre+ (n = 
3 mice), Ptpn11E76K/+Mx1-Cre+ (n = 3 mice), and Ptpn11E76K/+Vav1-Cre+ (n = 7 mice) 
mice at the same age were monitored at the indicated time points. Data shown in b–e are 
mean ± s.d. of all mice examined; **P < 0.01; ***P < 0.001; N.S., not significant. Source 
data are available online.
Extended Data Figure 3. Donor-cell-derived MPN is developed in Ptpn11E76K/+Mx1-Cre+ broad 
knock-in mice and Ptpn11D61G/+ global knock-in mice, but not Ptpn11E76K/+Vav1-Cre+ 
haematopoietic cell-specific knock-in mice transplanted with wild-type BM cells
BM cells (2 × 106) freshly collected from wild-type BoyJ mice (CD45.1+) were transplanted 
into lethally irradiated (1,100 cGy) Ptpn11E76K/+Mx1-Cre+, Ptpn11+/+Mx1-Cre+ (8 weeks 
after pI–pC administration), and Ptpn11E76K/+Vav1-Cre+ mice at 16-week old (CD45.2+). 
Spleen weights (n = 5 mice per group) (a), percentages of donor cell (CD45.1+) 
reconstitution (n = 8 mice per group) and percentages of donor cell-derived myeloid 
(Mac-1+Gr-1+) cells (n = 8 mice per group) in the peripheral blood of the recipients (b) were 
determined at the indicated time points following the transplantation. c, BM cells (1 × 106) 
freshly collected from wild-type BoyJ mice (CD45.1+) were transplanted into lethally 
irradiated 3–4-month old Ptpn11D61G/+ and Ptpn11+/+ (CD45.2+) mice (n = 14 and 17 mice, 
respectively). Recipients were monitored for MPN development for 8 months. Percentages 
of donor cell (CD45.1+)-derived Mac-1+ myeloid cells in the peripheral blood of recipients 
were determined. Representative results are shown. Data shown in a, b are mean ± s.d. of all 
mice examined; **P < 0.01; ***P < 0.001. Source Data for this figure are available online.
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Extended Data Figure 4. Ptpn11E76K/+ mutation in MSPCs and osteoprogenitors, but not 
differentiated osteoblasts or endothelial cells, in the BM microenvironment induces MPN
Cell-type-specific Ptpn11E76K knock-in mice as indicated were generated and monitored for 
MPN development. a, The ages of the microenvironmental cell-type-specific Ptpn11E76K/+ 
knock-in mice when they were euthanized for MPN diagnosis. b, Peripheral blood 
haematology was determined using the Hema True veterinary hematology analyzer. 
Mac-1+Gr-1+/− myeloid cells, B220+ B lymphoid, and CD3+ T-lymphoid cells in the BM 
were analysed by FACS. Karyotypes of MPN cells were examined by standard karyotyping 
analyses. HSCs in the peripheral blood were determined by multiparameter FACS. SSC/
CD45 profiles were also determined by FACS. CD115+Gr-1+ monocytes were highlighted in 
red. Cytokine sensitivity of BM myeloid progenitors was determined by CFU assays with a 
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range of GM-CSF concentrations. Transplantability of MPN cells was determined by 
transplantation of BM cells into lethally-irradiated BoyJ mice. Recipient mice were 
monitored for 6 months. All methods are described in Methods and/or related figure legends. 
c, BM-derived MSPCs were generated from the indicated mouse lines. The abundance of the 
neo cassette in genomic DNA was determined by qPCR (n = 3 mice per group). Data shown 
in c are mean ± s.d. of all mice examined. Statistical significance (***P < 0.001) was 
determined between the indicated cell-type-specific Ptpn11E76K/+ knock-in mice and 
Ptpn11E76K-neo/+Nestin-Cre− control mice. Source Data for this figure are available online.
Extended Data Figure 5. Ptpn11E76K/+ MSPCs do not directly activate HSCs
BM-derived MSPCs were enriched from Ptpn11E76K/+Nestin-Cre+ and Ptpn11+/+Nestin-
Cre+ mice, as described in Methods. MSPCs at the 2nd or 3rd passages were plated in 
regular 24-well plates (a) or lower chambers of transwells (b). Forty-eight hours later when 
the cells were confluent, HSCs (75–200) (Lin−Sca-1+c-Kit+CD150+CD48−Flk2−) sorted 
from Ptpn11E76K/+Mx1-Cre+ and Ptpn11+/+Mx1-Cre+ mice (8 weeks after pI–pC 
administration) were seeded in the same wells (a) or in upper chambers with the 0.4 µm pore 
size (b). The cells were co-cultured in StemSpan medium supplemented with cytokines TPO 
(50 ng ml−1), Flt3 ligand (50 ng ml−1), SCF (50 ng ml−1), IL-3 (20 ng ml−1), and IL-6 (20 
ng ml−1). Frequencies of myeloid (Mac-1+Gr-1+) cells that differentiated from HSCs were 
assayed by FACS analyses after 7–10 days of co-culture. Experiments were performed three 
times and similar results were obtained in each (see Supplementary Information). Results 
shown are mean ±s.d. of triplicates from one experiment; N.S., not significant. Source data 
are available online.
Supplementary Information is available in the online version of the paper.
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Extended Data Figure 6. Cytokines/chemokines are aberrantly produced by Ptpn11E76K/+ 
MSPCs
a, Spleen tissues freshly dissected from Ptpn11E76K/+Mx1-Cre+ and Ptpn11+/+Mx1-Cre+ 
mice (n = 3 mice per group) 12 weeks after pI–pC administration were gently smashed in 
PBS (0.1 g tissue per 1.0 ml). Supernatant collected was processed for cytokine–chemokine 
array analyses with the Mouse Cytokine Antibody Array Kit following the instructions 
provided by the manufacturer. Representative results from one pair of the mice are shown. b, 
MSPCs (CD45−Ter-119−CD31−CD140α+Sca-1+) were freshly isolated from paired 
Ptpn11E76K/+Nestin-Cre+ and Ptpn11+/+Nestin-Cre+ mice at 7–8 months old by FACS. Total 
RNA was extracted and processed for RNA-sequencing analyses as described in Methods. 
The correlation coefficient between the two groups was 0.954, verifying that the method was 
accurate (left). Genes with more than 2.0 fold increased (in red) or decreased (in green) 
mRNA levels are shown on the right. Secreted protein factors are indicated. c, HSCs sorted 
from wild-type C57BL/6 mice were cultured in the presence of IL-1β (10 ng ml−1), CCL3 
(20 ng ml−1), CCL4 (20 ng ml−1), or CCL12 (20 ng ml−1). Six days later, cells were 
collected and analysed for Mac-1+ myeloid cells, F4/80+ macrophages, and CD115+ 
monocytes by FACS. Data presented are mean ± s.d. of four independent experiments; ***P 
< 0.001. Source Data for this figure are available online.
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Extended Data Figure 7. Ptpn11E76K/+ mutation increases MSPC proliferation by enhancing cell 
signalling activities
a, Seven–ten-month-old Ptpn11E76K/+Nestin-Cre+ mice and Ptpn11+/+Nestin-Cre+ 
littermates were analysed. Femurs were processed for immunofluorescence staining with the 
indicated antibodies (n = 3 mice per group). Representative images are shown. b, BM cells 
(2 × 106 cells) freshly collected from the indicated mouse lines (n = 3 mice per group) were 
assessed by the CFU-F assay, as detailed in Methods. Statistical significance was determined 
between the indicated cell-type-specific Ptpn11E76K/+ knock-in mice and Ptpn11+/+Nestin-
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Cre+ control mice. c, d, MSPCs were enriched from Ptpn11E76K/+Nestin-Cre+ and 
Ptpn11+/+Nestin-Cre+ mice (n = 4 mice per group) as described in Methods. MSPCs were 
analysed for growth rates (c, left) and expression levels of Shp2 (c, right), and cell cycle 
distributions (d). e, Confluent MSPCs (n = 3 mice per group) were starved in serum and 
growth factor-free medium for 48 h and then stimulated with basic fibroblast growth factor 
(bFGF, 50 ng ml−1) for the indicated periods of time. Whole-cell lysates were prepared and 
examined for Erk, Akt, c-Src, and S6 activities by immunoblotting with anti-phospho-Erk, 
anti-phospho-Akt, anti-phospho-c-Src Y416, and anti-phospho-S6 antibodies. Blots were 
stripped and reprobed with anti-pan-Erk, anti-pan-Akt, anti-c-Src, anti-S6, and anti-Shp2 
antibodies to check protein loading and Shp2 levels. Densitometric analyses were performed 
to determine phosphorylation levels of the indicated proteins and normalized against protein 
loading levels (arbitrary units). Data shown in b–e are mean ± s.d. of all mice examined. *P 
< 0.05; **P < 0.01; ***P < 0.001. Source Data for this figure are available online.
Extended Data Figure 8. Ptpn11E76K/+ MSPCs recruit monocytes, but not macrophages, to the 
vicinity
a, Bone sections (one section per femur or tibia) prepared from Ptpn11E76K/+Prx1-Cre+ (n = 
4 mice) and Ptpn11+/+Prx1-Cre+ mice (n = 3 mice) at 6–7 months old were immunostained 
with the indicated antibodies and counterstained with DAPI. b–d, Bone sections (one section 
per femur or tibia) prepared from Ptpn11E76K/+Nestin-Cre+ and Ptpn11+/+Nestin-Cre+ mice 
at 7–10 months old were immunostained with the indicated antibodies and counterstained 
with DAPI (n = 5 mice per group) (b). The distance of HSCs (Lin–CD48–CD41–CD150+) 
from closest CD31+CD144+ endothelial cells was determined (n = 8 mice per group) (c). 
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The spatial relationship between HSCs (Lin−CD41−CD150+) and megakaryocytes (CD41+) 
was examined. HSCs within <8 µm of megakaryocytes were considered as close to 
megakaryocytes (n = 5 mice per group) (d). Representative images are shown in all panels.
Extended Data Figure 9. Administration of CCL3 receptor antagonists reverses MPN 
phenotypes in Ptpn11E76K/+Osx1-Cre+ mice
Ptpn11E76K/+Osx1-Cre+ mice at 6–7 months old were treated daily with the CCR1 
antagonist BX471 and the CCR5 antagonist Maraviroc or vehicle control for 23 days as 
described in Methods. Myeloid cells (Mac-1+Gr-1+) in the peripheral blood were determined 
at the indicated time points (n = 5 mice per group, each line represents one mouse) (a). Mice 
were euthanized at the end of the experiments. Monocytes (CD115+Gr-1+) (n = 5 and 6 mice 
for the antagonist and vehicle groups, respectively) in the BM, spleen, and peripheral blood 
were determined (b). BM cells were assayed by multiparameter FACS analyses to determine 
the pool size (c) of HSCs (Lin−Sca-1+c-Kit+CD150+CD48−Flk2−) (n = 5 and 6 mice for the 
antagonist and vehicle groups, respectively). Data shown in b, c are mean ± s.d. of all mice 
examined; ***P < 0.001. Source Data for this figure are available online.
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Extended Data Figure 10. Administration of CCL3 receptor antagonists mitigates MPN in 
Ptpn11E76K/+Mx1-Cre+ mice
Ptpn11E76K/+Mx1-Cre+ mice (4 weeks after pI–pC administration; n = 5 mice per group) 
were treated daily with the CCR1 and CCR5 antagonists or vehicle as described above. Mice 
were euthanized, and spleens were photographed and weighted (a). White blood cell counts 
(b) and myeloid cells (Mac-1+Gr-1+) (c) in the peripheral blood were determined at the 
indicated time points. Mac-1+Gr-1+ myeloid cells (d) and CD115+Gr-1+ monocytes (e) in 
the BM, spleen, peripheral blood, and liver were determined at the end of the experiments. 
Data shown in all panels are mean ± s.d. of all mice examined; *P < 0.05; **P < 0.01; ***P 
< 0.001. Source Data for this figure are available online.
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Figure 1. Ptpn11E76K/+ mutation in Nestin+ MSPCs aberrantly activates neighbouring wild-type 
HSCs, inducing MPN in Ptpn11E76K/+Nestin-Cre+ mice
7–12-month-old Ptpn11E76K/+Nestin-Cre+ and Ptpn11+/+Nestin-Cre+ mice were analysed. a, 
Spleen weights were determined (n = 17 mice per group). b, Cells isolated from BM, 
spleens, livers and lungs were assayed for Mac-1+Gr-1+ myeloid cells by FACS (n = 12 mice 
per group). c, Genomic DNA isolated from BM haematopoietic cells and BM-derived 
MSPCs was assayed for the abundance of the neo cassette by qPCR (n = 5 mice per group). 
d–f, BM cells were assayed by multiparameter FACS to determine the pool size (n = 8 mice 
per group) (d), cell cycle distribution (n = 6 mice per group) (e), and intracellular signalling 
activities (n = 3 mice per group) (f) of HSCs (Lin−Sca-1+c-Kit+CD150+CD48−Flk2−). g, 
BM cells collected from 8-month old Ptpn11E76K/+Nestin-Cre+ mice (CD45.2+) with MPN 
or moribund Ptpn11E76K/+Nestin-Cre+ mice (12 months old) with severe MPN were 
transplanted into lethally irradiated wild-type mice (WT) BoyJ mice (CD45.1+). In addition, 
BM cells collected from BoyJ mice were transplanted into 6-month-old Ptpn11E76K/+Nestin-
Cre+ mice. Recipients were monitored for MPN development for 6–8 months. Data shown in 
a–f are mean ± s.d. of all mice examined; *P < 0.05; **P < 0.01; ***P < 0.001. Source Data 
for this figure are available online.
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Figure 2. MPN that developed in Ptpn11E76K/+Vav1-Cre+ mice is less severe and less progressive 
than MPN developed in Ptpn11E76K/+Mx1-Cre+ mice
Ptpn11E76K/+Mx1-Cre+ and Ptpn11+/+Mx1-Cre+ mice (8 weeks after pI–pC administration), 
along with 16-week-old Ptpn11E76K/+Vav1-Cre+ and Ptpn11+/+Vav1-Cre+ mice were killed. 
a, Spleen weights were determined (n = 8 mice per group). b, Cells isolated from BM, 
spleens and livers were assayed for Mac-1+Gr-1+ myeloid cells (n = 8 mice per group). c, 
Ptpn11E76K/+Mx1-Cre+ and Ptpn11E76K/+Vav1-Cre+ mice administered with pI–pC were 
monitored for 12 months for acute leukaemia progression. d, Haematopoietic cells (CD45+), 
MSPCs (Sca-l+CD140α+CD45−Ter-119−CD31−), endothelial cells 
(CD45−Ter-119−CD31+), and osteoblasts (Sca-l−CD140α+CD45−Ter-119−CD31−) were 
sorted from the BM.
The abundance of the neo cassette in genomic DNA was determined by qPCR (n = 3 mice 
per group). e–h, BM cells collected from wild-type BoyJ mice were transplanted into 
Ptpn11E76K/+Mx1-Cre+, Ptpn11+/+Mx1-Cre+ (8 weeks following pI–pC treatment), and 
Ptpn11E76K/+Vav1-Cre+ (16 weeks old) mice. Recipients were monitored for MPN 
development for 6–8 months (e). Mac-1+Gr-1+ myeloid cells in the BM, spleen and liver 
were examined (n = 5 mice per group) (f). The pool size (n = 4 mice per group) (g) and 
intracellular signalling activities (n = 3 mice per group) (h) of donor HSCs were determined 
25 weeks following transplantation. Data shown in a, b, d, f–h are mean ± s.d. of all mice 
examined. Statistical significance was determined between Ptpn11E76K/+Mx1-Cre+ and 
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Ptpn11E76K/+Vav1-Cre+ groups; **P < 0.01; ***P < 0.001. Source Data for this figure are 
available online.
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Figure 3. IL-1β and CCL3 are overproduced by Ptpn11E76K/+ MPN cells and MSPCs, 
respectively
a, b, Chemokine–cytokine array analyses were performed with BM plasma collected from 
Ptpn11E76K/+Mx1-Cre+ and Ptpn11+/+Mx1-Cre+ mice (n = 3 mice per group) 12 weeks after 
pI–pC administration (a) and the culture medium of MSPCs derived from these mice (b). 
Representative results are shown. c, BM plasma collected from the indicated cell-type-
specific Ptpn11E76K/+ knock-in mice (7–8 months old; n = 3 mice per group) was assayed 
for the levels of IL-1β and CCL3 by ELISA. d, CCL3 levels in the culture medium of 
MSPCs derived from the indicated lines of Ptpn11E76K/+ knock-in mice (n = 3 mice per 
group) were determined by ELISA. e, Levels of IL-1β, CCL3, IL-6 and G-CSF produced by 
cells from patients with JMML with the indicated PTPN11 mutations, and healthy human 
apheresis or BM cells were determined by cytometric bead array assay. f, CCL3 and 
CXCL12 levels in the culture medium of MSPCs derived from patients with Noonan 
syndrome (NS) with the indicated PTPN11 mutations or healthy individuals were 
determined by cytometric bead array and ELISA assays, respectively. Each bar in e, f 
represents one patient or healthy individual. Data shown in c, d are mean ± s.d. of all mice 
examined. Statistical significance was determined between the indicated cell-type-specific 
Ptpn11E76K/+ knock-in mice and Ptpn11+/+Nestin-Cre+ control mice; *P < 0.05; **P < 0.01; 
***P < 0.001. Source Data for this figure are available online.
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Figure 4. Ptpn11E76K/+ MSPCs recruit monocytes to the vicinity by excessive production of 
CCL3, leading to the hyperactivation and displacement of neighbouring HSCs from the niche
7–10-month-old Ptpn11E76K/+Nestin-Cre+ mice and Ptpn11+/+Nestin-Cre+ littermates were 
analysed. a, Calvariums were processed for histopathological examination (haematoxylin 
and eosin (H&E) staining) and immunofluorescence staining with the indicated antibody. 
Slides were counterstained with the DNA dye DAPI (4',6-diamidino-2-phenylindole; n = 3 
mice per group). b–d, Bone sections (one section per femur or tibia) were immunostained 
with the indicated antibodies (n = 5 mice per group). The spatial relationship between 
monocytes (CD115+Gr-1+) and MSPCs (Nestin+) (b), and between HSCs 
(Lin−CD48−CD41−CD150+) and monocytes (c) or MSPCs (d), were examined. HSCs 
within <8 µm of monocytes or MSPCs were considered as close to these cells. e–h, Six–
seven-month-old Ptpn11E76K/+Osx1-Cre+ mice were treated with the CCR1 antagonist 
BX471 and the CCR5 antagonist Maraviroc or vehicle control for 23 days. Mice were killed, 
and spleens were weighted (n = 5 and 10 mice for the antagonist and vehicle groups, 
respectively) (e). White blood cell counts in the peripheral blood were determined at the 
indicated time points (n = 5 mice per group, each line represents one mouse) (f). Myeloid 
cells (Mac-1+Gr-1+) in the BM, spleen, and peripheral blood (PB) (n = 5 and 10 mice for the 
antagonist and vehicle groups, respectively) (g), and the cell cycle distribution of HSCs in 
the BM (n = 5 and 6 mice for the antagonist and vehicle groups, respectively) (h) were 
determined at the end of the experiments. Representative images are shown in a–d. Data 
shown in e, g, and h are mean ± s.d. of all mice examined; **P < 0.01; ***P < 0.001. Source 
Data for this figure are available online.
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